We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Algeta Enters Research Collaboration with Genzyme to Evaluate Thorium Platform
News

Algeta Enters Research Collaboration with Genzyme to Evaluate Thorium Platform

Algeta Enters Research Collaboration with Genzyme to Evaluate Thorium Platform
News

Algeta Enters Research Collaboration with Genzyme to Evaluate Thorium Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Algeta Enters Research Collaboration with Genzyme to Evaluate Thorium Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Algeta ASA has announced that it has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform.

Under the terms of the collaboration, Genzyme will provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially.

Thomas Ramdahl, Executive Vice President and Chief Technology Officer, said: “We are delighted to work with Genzyme on this important new approach to cancer treatment, which combines our cancer-killing payload thorium-227 with the novel antibody’s own target specificity and tumor cell degradation properties. Algeta has previously demonstrated the promise of our alpha-emitter thorium-227 as a payload and we now look forward to applying our Thorium platform to this novel antibody.”

Advertisement